AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean pressure gradient ≥31 mm Hg in reclassified group
Number of subjects: 174
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: Aortic valve calcium score
Number of subjects: 174
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP and myocardial perfusion reserve
Number of subjects: 174
Study 33287584 — intervention group
Group type: EXPERIMENTAL
Intervention: Troponin
Number of subjects: 174
Study 33287704 — intervention group
Group type: EXPERIMENTAL
Intervention: MwoA patients
Number of subjects: 72
Study 33287722 — intervention group
Group type: EXPERIMENTAL
Intervention: LdT (600 mg/day) for 24 weeks, followed by LdT monotherapy until 104 weeks
Number of subjects: 108
Study 33287748 — intervention group
Group type: EXPERIMENTAL
Intervention: Epileptiform discharges or other sharp activity on EEGs
Number of subjects: 86
Study 33287748 — intervention group
Group type: COMPARATOR
Intervention: No epileptiform discharges or other sharp activity on EEGs
Number of subjects: 86
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical or sexual IPV
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical IPV
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual IPV
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Women raised in households with history of IPV
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with no formal education
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Husbands with no formal education
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Muslim women
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Women younger than age 30
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Women members of NGO or microcredit organization
Number of subjects: 3966
Study 33287907 — intervention group
Group type: EXPERIMENTAL
Intervention: Disclosure of violence
Number of subjects: 3966
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest drain removal
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: Bladder catheter insertion
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC insertion
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-hospital transport
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical patients
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2130
Study 33287910 — intervention group
Group type: EXPERIMENTAL
Intervention: ICU stay duration
Number of subjects: 2130
Study 33288401 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation (RFA)
Number of subjects: 156
Study 33288401 — intervention group
Group type: COMPARATOR
Intervention: Surgical resection
Number of subjects: 156
Study 33288485 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofatumumab, etoposide, and high-dose cytarabine (OVA)
Number of subjects: 27
Study 33288485 — intervention group
Group type: COMPARATOR
Intervention: Salvage chemotherapy
Number of subjects: 27
Study 33288485 — intervention group
Group type: EXPERIMENTAL
Intervention: MRD-negative patients
Number of subjects: 27
Study 33288505 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative NT-proBNP measurements
Number of subjects: 37664
Study 33288505 — intervention group
Group type: EXPERIMENTAL
Intervention: Major thoracic surgery
Number of subjects: 37664
Study 33288505 — intervention group
Group type: EXPERIMENTAL
Intervention: Major nonthoracic surgery
Number of subjects: 37664
Study 33288505 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-risk surgery
Number of subjects: 37664
Study 33288505 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 37664
Study 33288587 — intervention group
Group type: EXPERIMENTAL
Intervention: CCR5 inhibition treatment
Number of subjects: 0
Study 33288660 — intervention group
Group type: EXPERIMENTAL
Intervention: Lurbinectedin
Number of subjects: 105
Study 33288749 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab (anti-PD-L1) combined with dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor) in cohort A
Number of subjects: 68
Study 33288749 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and trametinib given concomitantly in cohort B
Number of subjects: 68
Study 33288749 — intervention group
Group type: EXPERIMENTAL
Intervention: Durvalumab and trametinib given sequentially in cohort C
Number of subjects: 68
Study 33288819 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Partial Nephrectomy after intra-arterial Embolization (LPNE)
Number of subjects: 0
Study 33289099 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric dispersible tablet formulation
Number of subjects: 1306
Study 33289099 — intervention group
Group type: EXPERIMENTAL
Intervention: Paediatric powder for suspension
Number of subjects: 1306
Study 33289422 — intervention group
Group type: EXPERIMENTAL
Intervention: Early surgical aortic valve replacement (AVR)
Number of subjects: 481
Study 33289422 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 481
Study 33289422 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 481
Study 33289432 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 33289495 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of PAM-13 in oncology nursing practices
Number of subjects: 0
Study 33289495 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM-13 implementation
Number of subjects: 0
Study 33289495 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient's anxiety level, quality of life, and health literacy level
Number of subjects: 0
Study 33289590 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypomethylating agent (HMA) guadecitabine
Number of subjects: 25
Study 33289590 — intervention group
Group type: COMPARATOR
Intervention: HMA-treated patients
Number of subjects: 25
Study 33289590 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-treatment tumours
Number of subjects: 25
Study 33289613 — intervention group
Group type: EXPERIMENTAL
Intervention: Deep learning (DL) ventilation MRI using a U-Net-based DCNN model
Number of subjects: 114
Study 33289613 — intervention group
Group type: COMPARATOR
Intervention: Noble gas MRI
Number of subjects: 114
Study 33289660 — intervention group
Group type: EXPERIMENTAL
Intervention: Piezocision combined with buccal alveolar bone regeneration using a tunneling approach
Number of subjects: 10
Study 33289669 — intervention group
Group type: EXPERIMENTAL
Intervention: My Guide app
Number of subjects: 80
Study 33289669 — intervention group
Group type: COMPARATOR
Intervention: My Health app
Number of subjects: 80
Study 33289680 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfiltered cigarettes
Number of subjects: 40
Study 33289680 — intervention group
Group type: COMPARATOR
Intervention: Filtered cigarettes
Number of subjects: 40
Study 33289910 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A deficiency
Number of subjects: 234
Study 33289910 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency
Number of subjects: 234
Study 33289910 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E levels
Number of subjects: 234
Study 33289918 — intervention group
Group type: EXPERIMENTAL
Intervention: Copanlisib with gemcitabine and cisplatin
Number of subjects: 24
Study 33289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with temozolomide (TMZ)
Number of subjects: 29
Study 33289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with irinotecan (IRN)
Number of subjects: 29
Study 33289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) at 200 mg every day on D1-7 plus temozolomide (TMZ) at 30 mg/m
Number of subjects: 29
Study 33289920 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (NIR) with TMZ or IRN
Number of subjects: 29
Study 33289956 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin plus pegylated liposomal doxorubicin (PLD)
Number of subjects: 218
Study 33289960 — intervention group
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Number of subjects: 140
Study 33290093 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact force-guided radiofrequency ablation
Number of subjects: 333
Study 33290245 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Psychotherapy Tool (9-week electronically delivered cognitive behavioral therapy program)
Number of subjects: 80
Study 33290245 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified intervention)
Number of subjects: 80
Study 33290752 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (Norditropin®)
Number of subjects: 328
Study 33290995 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of radical hysterectomy (COMPL group, N = 361)
Number of subjects: 515
Study 33290995 — intervention group
Group type: COMPARATOR
Intervention: Abandonment of radical hysterectomy (ABAND group, N = 154)
Number of subjects: 515
Study 33290995 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall disease-free survival
Number of subjects: 515
Study 33290994 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation
Number of subjects: 50
Study 33291741 — intervention group
Group type: EXPERIMENTAL
Intervention: Trabectedin treatment
Number of subjects: 63
Study 33291741 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping for pharmacokinetic genes (CYP450 and ABC drug transporters)
Number of subjects: 63
Study 33291807 — intervention group
Group type: EXPERIMENTAL
Intervention: BoNT-A injections at baseline and visit 2 (3-6 months later)
Number of subjects: 204
Study 33292000 — intervention group
Group type: EXPERIMENTAL
Intervention: AACVPR protocol
Number of subjects: 76
Study 33292050 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated model (IM) approach to oral health interventions
Number of subjects: 0
Study 33292050 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily brushing/flossing
Number of subjects: 0
Study 33292183 — intervention group
Group type: EXPERIMENTAL
Intervention: Music-based sessions (7 sessions)
Number of subjects: 80
Study 33292183 — intervention group
Group type: COMPARATOR
Intervention: Therapeutic education sessions (7 sessions)
Number of subjects: 80
Study 33292297 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized unrestricted-calorie diet for 6 weeks (compliant subjects)
Number of subjects: 30
Study 33292297 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized unrestricted-calorie diet for 6 weeks (non-compliant subjects)
Number of subjects: 30
Study 33292400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (semi-structured dialog and information leaflet, postcard reminder)
Number of subjects: 357
Study 33292400 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 357
Study 33292400 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (physicians)
Number of subjects: 357
Study 33292400 — intervention group
Group type: COMPARATOR
Intervention: Control group (physicians)
Number of subjects: 357
Study 33292400 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison of vaccination rates
Number of subjects: 357
Study 33292400 — intervention group
Group type: EXPERIMENTAL
Intervention: Physicians
Number of subjects: 357
Study 33292514 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced recovery program plus goal-directed hemodynamic therapy (ERP + GDHT)
Number of subjects: 623
Study 33292514 — intervention group
Group type: COMPARATOR
Intervention: Enhanced recovery program (ERP)
Number of subjects: 623
Study 33292514 — intervention group
Group type: COMPARATOR
Intervention: Pre-ERP (historical control)
Number of subjects: 623
Study 33292514 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 623
Study 33292530 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (growth hormone) at a mean dose of 0.03 mg/kg/d (SD, 0.01 mg/kg/d)
Number of subjects: 129
Study 33292530 — intervention group
Group type: EXPERIMENTAL
Intervention: Somatropin (growth hormone)
Number of subjects: 129
Study 33292545 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative accelerated radiotherapy combined with neoadjuvant and adjuvant chemotherapy (6 cycles of doxorubicin 60 mg/m2)
Number of subjects: 20
Study 33292582 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem or piperacillin-tazobactam (specific dosages and duration not provided)
Number of subjects: 55
Study 33292582 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 3 (specific intervention not detailed)
Number of subjects: 55
Study 33292582 — intervention group
Group type: COMPARATOR
Intervention: Group 1 (specific intervention not detailed)
Number of subjects: 55
Study 33292598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet (KD) total meal replacement (TMR) program, 10g CH/day, 1600 kcal/day for 6 months
Number of subjects: 8
Study 33292598 — intervention group
Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet (KD) total meal replacement (TMR) program
Number of subjects: 8
Study 33292612 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day for 2 weeks
Number of subjects: 50
Study 33292612 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (in vitro on MCF-7 cells)
Number of subjects: 50
Study 33292651 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone-based hearing screening process and telemedicine specialty referral pathway
Number of subjects: 0
Study 33292651 — intervention group
Group type: COMPARATOR
Intervention: Standard primary care referral pathway
Number of subjects: 0
Study 33292659 — intervention group
Group type: EXPERIMENTAL
Intervention: MHH intervention (menstrual cup or reusable pads, analgesia, and MHH education)
Number of subjects: 1732
Study 33292659 — intervention group
Group type: EXPERIMENTAL
Intervention: MHH intervention (reusable pads)
Number of subjects: 1732
Study 33292659 — intervention group
Group type: EXPERIMENTAL
Intervention: MHH intervention (menstrual cups)
Number of subjects: 1732
Study 33292659 — intervention group
Group type: EXPERIMENTAL
Intervention: MHH intervention
Number of subjects: 1732
Study 33292671 — intervention group
Group type: EXPERIMENTAL
Intervention: Active phototherapy (8 sessions over 4 weeks)
Number of subjects: 20
Study 33292671 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 33292676 — intervention group
Group type: EXPERIMENTAL
Intervention: 16-week aerobic and resistance exercise intervention
Number of subjects: 100
Study 33292683 — intervention group
Group type: EXPERIMENTAL
Intervention: Health system intervention to improve kidney disease care
Number of subjects: 0
Study 33292683 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes
Number of subjects: 0
Study 33292695 — intervention group
Group type: EXPERIMENTAL
Intervention: Panretinal photocoagulation (PRP) treatment
Number of subjects: 21
Study 33292695 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline OCT-A area
Number of subjects: 21
Study 33292695 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline FA area
Number of subjects: 21
Study 33292695 — intervention group
Group type: EXPERIMENTAL
Intervention: Month 6 FA area
Number of subjects: 21
Study 33292695 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between OCT-A and FA area
Number of subjects: 21
Study 33292788 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold micropulse laser (SML)
Number of subjects: 120
Study 33292788 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection of ranibizumab
Number of subjects: 120
Study 33292788 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 120
Study 33292797 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (IFX)
Number of subjects: 810
Study 33292797 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (GLM)
Number of subjects: 810
Study 33292797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IFX and GLM
Number of subjects: 810
Study 33292822 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 50
Study 33292826 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-administered pediatric tuina
Number of subjects: 60
Study 33292826 — intervention group
Group type: COMPARATOR
Intervention: Parent-child interaction group (progressive muscle relaxation exercise)
Number of subjects: 60
Study 33292848 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone check-ins to collect data about implementation activities
Number of subjects: 19
Study 33292854 — intervention group
Group type: EXPERIMENTAL
Intervention: HEAL-ABC intervention with behaviour change theory and supportive telephone calls every 2 weeks for 3 months, then monthly for 6 months
Number of subjects: 72
Study 33292854 — intervention group
Group type: COMPARATOR
Intervention: Usual care with access to public domain resources
Number of subjects: 72
Study 33293291 — intervention group
Group type: COMPARATOR
Intervention: Living in the least deprived areas
Number of subjects: 9176
Study 33293291 — intervention group
Group type: EXPERIMENTAL
Intervention: Ever been homeless
Number of subjects: 9176
Study 33293291 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 9176
Study 33293291 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance misuse
Number of subjects: 9176
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidence of new-onset type 3c diabetes mellitus during follow-up
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life analyses (SF-36, Gastrointestinal Quality of Life Index)
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Montreal cognitive assessment
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Organ system physiological performance
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiomics predictors of AP severity
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of premature cellular senescence
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiparameter MRI scan
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Echocardiography
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary function testing
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiopulmonary exercise testing
Number of subjects: 0
Study 33293311 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse-wave analysis
Number of subjects: 0
Study 33293313 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate or severe pain trajectories
Number of subjects: 305
Study 33293313 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe pain trajectory
Number of subjects: 305
Study 33293313 — intervention group
Group type: COMPARATOR
Intervention: Low final pain trajectories
Number of subjects: 305
Study 33293316 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II type 1 receptor blockers (ARBs)
Number of subjects: 497
Study 33293316 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuing ARBs
Number of subjects: 497
Study 33293316 — intervention group
Group type: COMPARATOR
Intervention: ARB-exposed patients
Number of subjects: 497
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial ischaemia (MSIMI)
Number of subjects: 126
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental stress-induced myocardial blood flow (MBF) change
Number of subjects: 126
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine vasodilator stress-induced MBF change
Number of subjects: 126
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Reactive Hyperemia Index
Number of subjects: 126
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral arterial tonometry or digital vasomotor response
Number of subjects: 126
Study 33293388 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood and psychometric tests
Number of subjects: 126
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression (PROMIS score ≥55)
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: PROMIS Physical Function
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index (BI)
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: EuroQoL five dimensions (EQ-5D)
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Rankin Score
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported quality of life
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Marital status
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Foreign-born status
Number of subjects: 450
Study 33293392 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidity
Number of subjects: 450
Study 33294203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropinirole 0.5 mg daily and Gabapentin 100 mg daily (combined treatment)
Number of subjects: 72
Study 33294203 — intervention group
Group type: COMPARATOR
Intervention: Double dummy placebo control (neither ropinirole nor gabapentin)
Number of subjects: 72
Study 33294303 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate health dietary combination formulation (one daily capsule for 60 days)
Number of subjects: 30
Study 33294812 — intervention group
Group type: EXPERIMENTAL
Intervention: MI-Opioid Taper
Number of subjects: 104
Study 33294812 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 104
Study 33294862 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized neoantigen cancer vaccine plus anti-PD-1 therapy
Number of subjects: 21